Development and characterization of a multimeric recombinant protein using the spike protein receptor binding domain as an antigen to induce SARS-CoV-2 neutralization.

ABSTRACT:

Background

SARS-CoV2 virus, responsible for the COVID-19 pandemic, has four structural proteins and 16 nonstructural proteins. S-protein is one of the structural proteins exposed on the virus surface and is the main target for producing neutralizing antibodies and vaccines. The S-protein forms a trimer that can bind the angiotensin-converting enzyme 2 (ACE2) through its receptor binding domain (RBD) for cell entry.

Aims

The goal of this study was to express in HEK293 cells a new RBD recombinant protein in a constitutive and stable manner in order to use it as an alternative immunogen and diagnostic tool for COVID-19.

Materials & methods

The protein was designed to contain an immunoglobulin signal sequence, an explanded C-terminal section of the RBD, a region responsib

SUBMITTER: de Lima VA 

PROVIDER: S-EPMC11273545 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature